CUREVO

curevo-logo

Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.

#SimilarOrganizations #People #Financial #Website #More

CUREVO

Social Links:

Industry:
Biopharma Biotechnology

Founded:
2018-01-01

Website Url:
http://www.curevovaccine.com

Total Employee:
1+

Status:
Active

Contact:
1(206)492-5722

Total Funding:
60 M USD

Technology used in webpage:
Domain Not Resolving Microsoft Exchange Online


Similar Organizations

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

eikonoklastes-therapeutics-logo

Eikonoklastes Therapeutics

Eikonoklastes Therapeutics is a preclinical-stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies.

Current Employees Featured

george-simeon_image

George Simeon
George Simeon CEO @ Curevo
CEO
2019-02-01

Investors List

janus-henderson-investors_image

Janus Henderson Investors

Janus Henderson Investors investment in Series A - Curevo

e-networks-venture-investment_image

E&Investment

E&Investment investment in Series A - Curevo

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series A - Curevo

green-cross-holdings-corp_image

Green Cross Holding Corp

Green Cross Holding Corp investment in Series A - Curevo

adjuvant-capital_image

Adjuvant Capital

Adjuvant Capital investment in Series A - Curevo

Official Site Inspections

http://www.curevovaccine.com

  • Host name: 192.0.78.148
  • IP address: 192.0.78.148
  • Location: San Francisco United States
  • Latitude: 37.7506
  • Longitude: -122.4121
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94110

Loading ...

More informations about "Curevo"

Home - Curevo Vaccine

Focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical โ€ฆSee details»

Curevo - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number 1(206)492-5722 Curevo is a clinical-stage biotech firm focused on producing vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the โ€ฆSee details»

Management Team - Curevo Vaccine

Executive Team Board of Directors Scientific Advisors Executive Team Linkedin George Simeon CEO & Board Director George Simeon is the CEO of Curevo Vaccine. He joined Curevo at โ€ฆSee details»

Curevo Vaccine - LinkedIn

Curevo Vaccine Biotechnology Research Bothell, Washington 2,034 followers Seattle-based clinical-stage biotech company with a lead product CRV-101, a sub-unit vaccine for the โ€ฆSee details»

Curevo Vaccine Company Profile 2024: Valuation, โ€ฆ

Curevo Vaccine General Information Description. Developer of a clinical-stage adjuvanted subunit vaccine intended to improve efficacy and broaden immune response. The company leverages its proprietary platform to design and โ€ฆSee details»

Curevo Vaccine Inc. - BIO Investor Forum | BIO

The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... www.curevovaccine.com. โ€ฆSee details»

Curevo Vaccine Overview - Salary.com

Discover essential details about Curevo Vaccine, including address, contact, and journey of our company's evolution.See details»

Curevo Vaccine - htgc.com

Curevo Vaccine is a privately held, clinical-stage biotechnology company based near Seattle and dedicated to reducing the burden of infectious disease by developing safe and highly effective โ€ฆSee details»

Curevo Inc. | Insights

Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»

Our History - Curevo Vaccine

Our Mission Safety. Supply. Efficacy. By combining excellence in protein and adjuvant biology, we are focused on creating a new generation of adjuvanted subunit vaccines of global โ€ฆSee details»

Curevo Presents Positive Shingles Vaccine Outcomes Data

Oct 31, 2024 Contacts David Miller Sr. Director of Strategic Communications [email protected] More in Markets View All. Fidelityโ€™s Jurrien Timmer on Why the Stock โ€ฆSee details»

P4VE Funded Partners | P4VE | CDC - Centers for Disease Control โ€ฆ

Jun 21, 2024 A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS. A lock ( ) or https:// means you've safely connected to the โ€ฆSee details»

Curevo, Inc. - ่ฏ็‰ฉ็ฎก็บฟ_ไธ“ๅˆฉ_ไธดๅบŠ่ฏ•้ชŒ_ๆŠ•่ž่ฅๆ”ถ_ๆœ€ๆ–ฐ่ฏ โ€ฆ

-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, โ€ฆSee details»

Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial โ€ฆ

Sep 15, 2022 -- Phase 2b trial enrolled 678 participants in six months-- Topline data from Phase 2b head-to-head trial of CRVโ€‘101 against Shingrix® expected in early 2023. SEATTLE, Sept. โ€ฆSee details»

GC Pharma to Establish Curevo - Curevo Vaccine

May 18, 2018 As a non-profit global research organization, MIBR (Mogam Institute for Biomedical Research) is engaged in basic drug discovery research to combat infectious โ€ฆSee details»

Cision PR Newswire - NBC4 WCMH-TV

Sep 15, 2022 -- Phase 2b trial enrolled 678 participants in six months -- Topline data from Phase 2b head-to-head trial of CRVโ€‘101 against Shingrix® expected in early 2023 SEATTLE, Sept. โ€ฆSee details»

Curevo Presents Positive Shingles Vaccine Outcomes Data

Oct 31, 2024 โ€” Updated data will be featured in an oral presentation at the World Vaccine Congress Barcelona, 31 October 2024, in Theatre 5 at 13:30 CEST . SEATTLE, Oct. 31, 2024 โ€ฆSee details»

Partnerships - Curevo Vaccine

Through our strategic partnership, we can leverage broader expertise and a global perspective. By partnering with GC Pharma and Mogam Biomedical Research Institute, we focus on โ€ฆSee details»

How much do Curevo Vaccine employees make? | Salary.com

The average annual salary of Curevo Vaccine is estimated to be approximate $101,335 per year. The majority pay is between $89,271 to $114,440 per year. Visit Salary.com to find out Curevo โ€ฆSee details»

Careers - Curevo Vaccine

Curevo is a proud Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, age, sex, national origin, disability โ€ฆSee details»

linkstock.net © 2022. All rights reserved